[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3475 Introduced in House (IH)]

111th CONGRESS
  1st Session
                                H. R. 3475

 To amend the Public Health Service Act to double the amount of funds 
authorized to be appropriated to the National Institutes of Health for 
  medical research with the greatest potential for near-term clinical 
                                benefit.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             July 31, 2009

  Mr. Forbes introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
 To amend the Public Health Service Act to double the amount of funds 
authorized to be appropriated to the National Institutes of Health for 
  medical research with the greatest potential for near-term clinical 
                                benefit.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Accelerate Cures for Patients Act of 
2009''.

SEC. 2. ADDITIONAL NIH FUNDING FOR RESEARCH WITH GREATEST POTENTIAL FOR 
              NEAR-TERM CLINICAL BENEFIT.

    Title IV of the Public Health Service Act (42 U.S.C. 281 et seq.) 
is amended by inserting after section 402A the following:

``SEC. 402A-1. ADDITIONAL FUNDING FOR RESEARCH WITH GREATEST POTENTIAL 
              FOR NEAR-TERM CLINICAL BENEFIT.

    ``In addition to the amount authorized to be appropriated each 
fiscal year pursuant to section 402A to conduct or support medical 
research under this title, there is authorized to be appropriated an 
equal amount for medical research (relating to cancer, cardiovascular 
disease, diabetes, Alzheimer's disease, Parkinson's disease, or other 
diseases or conditions) that (as determined by the Secretary) has the 
greatest potential for near-term clinical benefit in human patients, as 
indicated by substantial evidence from basic research or by substantial 
clinical evidence. Such evidence may include but is not limited to--
            ``(1) evidence of improvement in one or more human patients 
        suffering from illness or injury, as documented in reports by 
        professional medical or scientific associations or in peer-
        reviewed medical or scientific literature; or
            ``(2) approval for use in human trials by the Food and Drug 
        Administration.''.
                                 <all>